Article info
Chest clinic
Case based discussion
Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage
- Correspondence to Dr Nadia Nathan, Pediatric Pulmonology and Reference centre for rare lung diseases, AP-HP, Trousseau Hospital, Sorbonne University, Paris 75012, France; nadia.nathan{at}aphp.fr
Citation
Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage
Publication history
- Received July 29, 2019
- Revised October 1, 2019
- Accepted October 4, 2019
- First published October 30, 2019.
Online issue publication
December 13, 2019
Article Versions
- Previous version (30 October 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.